Efficacy and safety of dapagliflozin according to baseline blood pressure - observations from DECLARE-TIMI 58 Trlial

被引：0
|
作者：
Furtado, R. [1 ]
Raz, I [2 ]
Goodrich, E. L. [3 ]
Sabatine, M. S. [3 ]
Wiviott, S. D. [3 ]
机构：
[1] Hosp Israelita Albert Einstein, Sao Paulo, Brazil
[2] Hebrew Univ Jerusalem, Hadassah Med Ctr, Diabet Unit, Jerusalem, Israel
[3] Harvard Med Sch, Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA
来源：
EUROPEAN HEART JOURNAL | 2020年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3063 / 3063
页数：1
相关论文
共 50 条
  • [21] Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58
    Bonaca, Marc P.
    Wiviott, Stephen D.
    Zelniker, Thomas A.
    Mosenzon, Ofri
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Goodrich, Erica L.
    De Mendonca Furtado, Remo Holanda
    Wilding, John P. H.
    Cahn, Avivit
    Gause-Nilsson, Ingrid A. M.
    Johanson, Per
    Fredriksson, Martin
    Johansson, Peter A.
    Langkilde, Anna Maria
    Raz, Itamar
    Sabatine, Marc S.
    CIRCULATION, 2020, 142 (08) : 734 - 747
  • [22] Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus Insights From the DECLARE-TIMI 58 Trial
    Zelniker, Thomas A.
    Bonaca, Marc P.
    Furtado, Remo H. M.
    Mosenzon, Ofri
    Kuder, Julia F.
    Murphy, Sabina A.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Budaj, Andrzej
    Kiss, Robert G.
    Padilla, Francisco
    Gause-Nilsson, Ingrid
    Langkilde, Anna Maria
    Raz, Itamar
    Sabatine, Marc S.
    Wiviott, Stephen D.
    CIRCULATION, 2020, 141 (15) : 1227 - 1234
  • [23] Cardiovascular Risk Stratification and Efficacy of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 Trial
    Oyama, Kazuma
    Wiviott, Stephen D.
    Raz, Itamar
    Cahn, Avivit
    Goodrich, Erica
    Bhatt, Deepak L.
    Leiter, Lawrence
    McGuire, Darren K.
    Wilding, John
    Gause-Nilsson, Ingrid A.
    Mosenzon, Ofri
    Sabatine, Marc S.
    Bohula, Erin A.
    CIRCULATION, 2020, 142
  • [24] Effect of Dapagliflozin in Reducing Recurrent Myocardial Infarction of Different Infarct Types and Sizes: Insights From Declare-Timi 58
    Furtado, Remo H.
    Bonaca, Marc P.
    Zelniker, Thomas A.
    Raz, Itamar
    Goodrich, Erica
    Mosenzon, Ofri
    Murphy, Sabina
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John
    Gause-Nilsson, Ingrid A.
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Wiviott, Stephen
    CIRCULATION, 2019, 140
  • [25] Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
    Cahn, Avivit
    Wiviott, Stephen D.
    Mosenzon, Ofri
    Goodrich, Erica L.
    Murphy, Sabina A.
    Yanuv, Ilan
    Rozenberg, Aliza
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Gause-Nilsson, Ingrid A. M.
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Raz, Itamar
    DIABETES CARE, 2022, 45 (04) : 938 - 946
  • [26] Estimating healthcare resource implications associated with use of dapagliflozin: model predictions using data from the DECLARE-TIMI 58 trial
    McEwan, P.
    Bennett, H.
    Kartman, B.
    Edmonds, C.
    Gause-Nilsson, I.
    Wilding, J.
    DIABETOLOGIA, 2019, 62 : S396 - S397
  • [27] FIBROBLAST GROWTH FACTOR-23, CARDIORENAL OUTCOMES, AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM DECLARE-TIMI 58
    Berg, David
    Wiviott, Stephen D.
    Raz, Itamar
    Jarolim, Petr
    Goodrich, Erica L.
    Mosenzon, Ofri
    Cahn, Avivit
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Gause-Nilsson, Ingrid
    Hammarstedt, Ann
    Oscarsson, Jan
    Sabatine, Marc Steven
    Morrow, David A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1526 - 1526
  • [28] Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58
    Cahn, Avivit
    Raz, Itamar
    Leiter, Lawrence A.
    Mosenzon, Ofri
    Murphy, Sabina A.
    Goodrich, Erica L.
    Yanuv, Ilan
    Rozenberg, Aliza
    Bhatt, Deepak L.
    McGuire, Darren K.
    Wilding, John P. H.
    Gause-Nilsson, Ingrid A. M.
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Wiviott, Stephen D.
    DIABETES CARE, 2021, 44 (05) : 1159 - 1167
  • [29] Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure in DECLARE-TIMI 58
    Zelniker, T.
    Morrow, D.
    Mosenzon, O.
    Goodrich, E.
    Murphy, S.
    Deepak, B.
    Leiter, L.
    McGuire, D.
    Gause-Nilsson, I.
    Langkilde, A. M.
    Raz, I.
    Sabatine, M.
    Wiviott, S.
    WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : S170 - S171
  • [30] Effect of dapagliflozin on atrial fibrillation/flutter in patients with Type 2 Diabetes mellitus: insights from the DECLARE-TIMI 58 trial
    Zelniker, T.
    Bonaca, M.
    Mosenzon, O.
    Kuder, J.
    Murphy, S.
    Remo, F.
    Deepak, B.
    Leiter, L.
    McGuire, D.
    Wilding, J.
    Budaj, A.
    Kiss, G.
    Padilla, F.
    Gause-Nilsson, I.
    Langkilde, A. M.
    Raz, I.
    Sabatine, M.
    Wiviott, S.
    WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : S158 - S158
12345